[go: up one dir, main page]

AR023534A1 - VACCINE. - Google Patents

VACCINE.

Info

Publication number
AR023534A1
AR023534A1 ARP000101807A ARP000101807A AR023534A1 AR 023534 A1 AR023534 A1 AR 023534A1 AR P000101807 A ARP000101807 A AR P000101807A AR P000101807 A ARP000101807 A AR P000101807A AR 023534 A1 AR023534 A1 AR 023534A1
Authority
AR
Argentina
Prior art keywords
vaccine formulation
vaccine
cpgimmunostimulant
rsv
elderly
Prior art date
Application number
ARP000101807A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9915106.0A external-priority patent/GB9915106D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR023534A1 publication Critical patent/AR023534A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion se refiere a una formulacion de vacuna que comprende un antígeno del virus respiratorio sincitial (RSV) y un oligonucleotido CpGinmunoestimulante, a procedimientos de preparacion de la formulacion de vacuna y a su uso en medicina. Puedenincluirse antígenos adicionales para proporcionarnuevas vacunas de combinacion para su administracion a ninos, a adultos y a ancianos.The invention relates to a vaccine formulation comprising a respiratory syncytial virus (RSV) antigen and a CpGimmunostimulant oligonucleotide, methods of preparing the vaccine formulation and its use in medicine. Additional antigens may be included to provide new combination vaccines for administration to children, adults and the elderly.

ARP000101807A 1999-04-20 2000-04-18 VACCINE. AR023534A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9915106.0A GB9915106D0 (en) 1999-06-28 1999-06-28 Vaccine

Publications (1)

Publication Number Publication Date
AR023534A1 true AR023534A1 (en) 2002-09-04

Family

ID=26315443

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101807A AR023534A1 (en) 1999-04-20 2000-04-18 VACCINE.

Country Status (7)

Country Link
EP (1) EP1171158A2 (en)
AR (1) AR023534A1 (en)
AU (1) AU762857B2 (en)
CA (1) CA2370708A1 (en)
CO (1) CO5300406A1 (en)
HK (1) HK1045099A1 (en)
WO (1) WO2000062802A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020098199A1 (en) 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) * 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en) 2000-03-10 2007-01-02 Dynavax Technologies Corporation Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
WO2002011761A2 (en) * 2000-08-10 2002-02-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine against rsv
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110052237A (en) * 2019-04-19 2019-07-26 贺州学院 A kind of preparation method of porous powdered whiting adsorbent material
WO2021178306A1 (en) 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
CA3202133A1 (en) * 2020-12-16 2022-06-23 Martin Gohlke Method for quantifying cpg-containing oligonucleotides in formulations comprising alum

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7015493A (en) * 1969-11-14 1971-05-18
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU6908598A (en) * 1996-10-29 1998-05-22 Smithkline Beecham Biologicals (Sa) Purification of respiratory syncytial virus antigens
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE69932717T2 (en) * 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY

Also Published As

Publication number Publication date
AU762857B2 (en) 2003-07-10
EP1171158A2 (en) 2002-01-16
AU4552500A (en) 2000-11-02
HK1045099A1 (en) 2002-11-15
CA2370708A1 (en) 2000-10-26
WO2000062802A2 (en) 2000-10-26
CO5300406A1 (en) 2003-07-31
WO2000062802A3 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
AR032597A1 (en) USE OF ANTIGENS OF THE VIRUS OF THE INACTIVATED FLU, IN THE PREPARATION OF VACCINES OF A SINGLE INTRANASAL DOSE; METHOD FOR THE PROPHYLAXIS OF DISEASES OR OF INFLUENCES IN PATIENTS; EQUIPMENT THAT INCLUDES SUCH VACCINES IN SINGLE DOSE AND METHOD FOR MANUFACTURING VACCINES FOR THE FLU FOR APLI
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
NO20015073D0 (en) vaccinations
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DK1361890T3 (en) Influenza vaccine formulations for intradermal administration
ATE350057T1 (en) VACCINE COMPOSITION
ES2398451T3 (en) Vaccine Adjuvant
AR023534A1 (en) VACCINE.
ATE270707T1 (en) ENTEPNEUMOVIRUS AND CORRESPONDING VACCINE
EP2066332A4 (en) INFLUENZA VACCINE COMPRISING A MIXTURE OF MANNANE AND ANTIGEN OF INFLUENZA
RU2017137357A (en) QUICKLY DISPOSABLE DOSAGE FORM OF THE ORAL VACCINES WHICH USE STARCH
UY26882A1 (en) NEW TREATMENT
ATE422364T1 (en) MULTIVALENT IMMUNOGENIC COMPOSITION CONTAINING AN RSV SUBUNIT COMPOSITION AND AN INFLUENZA VIRUS PREPARATION
PT1024824E (en) COMPOSITION OF SOLID DISPERSIVAL VACCINE FOR ORAL ADMINISTRATION
WO2001095934A3 (en) The use of plant oil-bodies in vaccine delivery systems
AR023536A1 (en) VACCINES
WO2003050135A3 (en) Use a parapox b2l protein to modify immune responses to administered antigens
BR0207899A (en) Combination immunogen for sequential administration of components to elicit an immune response against papillomavirus, a pharmaceutical product, use of a pharmaceutical product, and method for eliciting an immune response against papillomavirus in a patient
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
AR037908A1 (en) A BIOMASS IN AVIAN EMBRYO PARTICLES FOR THE PRODUCTION OF VIRUS ANTIGENS
TH62589A (en) Hepatitis B surface antigens, mucosal immunosuppressants, formulated mixtures
ECSP961797A (en) VACCINES INCLUDING AN ANTIGEN CONJUGATE POLYSACCHARIDE
Pickering et al. MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
MD1855F1 (en) Method of poultry immunization against viral infections (variants)
SG160386A1 (en) Novel composition